Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 20;9(2):e70094.
doi: 10.1002/hem3.70094. eCollection 2025 Feb.

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia

Anna Maria Frustaci  1 , Arianna Zappaterra  1   2 , Andrea Galitzia  3 , Andrea Visentin  4 , Michele Merli  5 , Rita Rizzi  6 , Isacco Ferrarini  7 , Simone Ferrero  8 , Vanessa Innao  9 , Claudia Baratè  10 , Pierluigi Zinzani  11   12 , Benedetta Puccini  13 , Francesco Autore  14 , Monica Tani  15 , Angela Ferrari  16 , Gioacchino Catania  17 , Maura Nicolosi  18 , Raffaella Pasquale  19 , Marina Motta  20 , Roberta Murru  21 , Silvia Gambara  22 , Francesca Rezzonico  23 , Marzia Varettoni  24 , Emanuele Cencini  25 , Enrico Lista  26 , Nicolò Danesin  4 , Bianca Maria Granelli  1   2 , Marina Deodato  1 , Francesco Piazza  4 , Alessandra Tedeschi  1
Affiliations

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia

Anna Maria Frustaci et al. Hemasphere. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Anna Maria Frustaci received honoraria from Janssen, Beigene, Abbvie, AstraZeneca. Andrea Visentin participated scientific advisory boards organized by Johnson & Johnson, Abbvie, AstraZeneca, BeiGene, Takeda. Michele Merli participated scientific advisory boards organized by Eli Lilly. Alessandra Tedeschi received consulting fees and travel support for scientific events from Janssen, Beigene, Abbvie, Lilly, AstraZeneca. Andrea Visentin received advisory board participation fees from Janssen, Abbvie, Beigene, CSL Behring, Astrazeneca, Beigene, and Takeda. Isacco Ferrarini reports research fundings from Abbvie, BeiGene, and Eli‐Lilly. Simone Ferrero is a consultant for Janssen, EUSA Pharma, Recordati, Abbvie, and Sandoz; is on the advisory board of Janssen, EUSA Pharma, Recordati, Incyte, Roche, Astra Zeneca, and Italfarmaco; received speaker's honoraria from Janssen, EUSA Pharma, Recordati, Lilly, Beigene, Gilead, Novartis, Sandoz, and Gentili; and received research funding from Gilead, Incyte and Morphosys. Roberta Murru received scientific advisory board participation fees and travel support from Abbvie, AstraZeneca, Beigene, Johnson & Johnson. Marzia Varettoni participated scientific advisory boards and received speaker honoraria from Abbvie, AstraZeneca, Beigene and received advisory board participation fees from Johnson & Johnson. Francesco Piazza participated to advisory board and received speaker honoraria from Kite Gilead, Roche, and BeiGene and participated to advisory board from Abbvie and Johnson & Johnson.

Figures

Figure 1
Figure 1
Progression‐free survival (A) and overall survival (B) for all progressive and intolerant patients, and progression‐free survival (C) and overall survival (D) according to number of previous lines at cBTK‐S.
See this image and copyright information in PMC

References

    1. Grunenberg A, Buske C. How to manage waldenstrom's macroglobulinemia in 2024. Cancer Treat Rev. 2024;125:102715. 10.1016/j.ctrv.2024.102715 - DOI - PubMed
    1. U.S. Food and Drug Administration (FDA) . FDA expands approved use of Imbruvica (ibrutinib) for Waldenström's macroglobulinemia. Accessed January 13, 2025. https://www.drugs.com/newdrugs/fda-expands-approved-imbruvica-ibrutinib-...
    1. U.S. Food and Drug Administration (FDA) . FDA approves zanubrutinib for Waldenström's macroglobulinemia. Accessed January 13, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023;41:5099‐5106. 10.1200/JCO.22.02830 - DOI - PMC - PubMed
    1. Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B‐cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open‐label, single‐arm study. Lancet Haematol. 2023;10:e35‐e45. 10.1016/S2352-3026(22)00320-9 - DOI - PubMed

LinkOut - more resources